Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Ladoire

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 6, 2023
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II studyMaud Velev, Cécile Dalban, Christine Chevreau, et al.
European Journal of Cancer (Oxford, England : 1990)|March 30, 2024
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapyNicolas Roussot, Guillaume Constantin, Isabelle Desmoulins, et al.
Cancer Cell|January 20, 2022
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cellsEmeric Limagne, Lisa Nuttin, Marion Thibaudin, et al.
The New England Journal of Medicine|June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerMario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2022
Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional studySylvain Ladoire, Emilie Rederstorff, Vincent Goussot, et al.
Journal of Extracellular Vesicles|June 30, 2020
Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot studyGaëtan Chanteloup, Marine Cordonnier, Nicolas Isambert, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2021
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov studySylvain Ladoire, Vincent Goussot, Emilie Redersdorff, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
The Lancet. Oncology|October 2, 2022
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trialFrançois-Clément Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, et al.
European Urology Focus|July 30, 2017
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre StudyAndrea Necchi, Gregory R Pond, Marc C Smaldone, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|February 6, 2023
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II studyMaud Velev, Cécile Dalban, Christine Chevreau, et al.
European Journal of Cancer (Oxford, England : 1990)|March 30, 2024
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapyNicolas Roussot, Guillaume Constantin, Isabelle Desmoulins, et al.
Cancer Cell|January 20, 2022
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cellsEmeric Limagne, Lisa Nuttin, Marion Thibaudin, et al.
The New England Journal of Medicine|June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerMario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2022
Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional studySylvain Ladoire, Emilie Rederstorff, Vincent Goussot, et al.
Journal of Extracellular Vesicles|June 30, 2020
Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot studyGaëtan Chanteloup, Marine Cordonnier, Nicolas Isambert, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2021
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov studySylvain Ladoire, Vincent Goussot, Emilie Redersdorff, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
The Lancet. Oncology|October 2, 2022
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trialFrançois-Clément Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, et al.
European Urology Focus|July 30, 2017
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre StudyAndrea Necchi, Gregory R Pond, Marc C Smaldone, et al.
Pageof 17